1444 Results
Sort By:
Published on April 17, 2023
An “off-the-shelf” allogeneic CAR T-cell therapy, developed by Allogene Therapeutics and tested by the University of Texas MD Anderson Cancer Center, showed promising results in a Phase I trial to treat patients with metastatic clear cell renal cell carcinoma. The advent of immunotherapy revolutionized cancer treatment. Combined gene and cell…
Published on March 30, 2023
A newly created nanoparticle that carries a messenger RNA (mRNA) payload that can be administered to the lungs may offer a method to provide an inhalable treatment for cystic fibrosis and other lung diseases. Designed by engineers at MIT and the University of Massachusetts Medical School and applied in a…
Published on March 22, 2023
Gut microorganisms influence non-Hodgkin lymphoma patient outcomes to chimeric antigen receptor T-cell (CAR T) therapy, according to a recent multinational research collaboration. A key finding of this study was that patients who had higher levels of the bacterium Bifidobacterium longum had an improved overall survival rate after CAR T. The team…
Published on March 16, 2023
Researchers at the Perelman School of Medicine at the University of Pennsylvania have developed a new and improved CAR T cell therapy approach for solid tumors by simultaneously knocking out two inflammatory regulators and boosting T cell expansion. CAR T cells are immune cells taken from an individual patient and genetically…
Published on March 1, 2023
Researchers from the Department of Health Sciences and Technology, ETH Zurich, have for the first time mapped the effects of Benzo(a) pyrene (BaP) exposure on lung cells, down to the single-nucleotide level. BaP, found in both cigarette and industrial smoke, is known to cause damage to DNA. The team’s study,…
Published on January 19, 2023
Researchers in Canada have helped explain how the PCSK9 protein degrades low-density lipoprotein (LDL) receptors. Their findings add key insight to the understanding of how atherosclerosis develops. The richest cholesterol particles in the bloodstream, LDLs are strongly linked to cardiovascular disease. But PCSK9 also plays a role in cancer. The…
Published on January 11, 2023
A new study reveals that circadian clock proteins are actively involved in the development of hepatocellular carcinoma (HCC) and provide a mechanistic explanation for how liver cancer cells use these proteins to grow. The research, published in the journal Proceedings of the National Academy of Sciences, also found that inhibiting…
Published on January 11, 2023
Researchers at the Medical University of Vienna have identified “exhausted” T cells in lymphoma patients as a potent biomarker that can be used to predict the success of CAR-T cell therapy in patients. In recent years, CAR-T cell therapy has been approved for lymphoma patients. CAR-T cells are lymphocytes taken from…
Published on December 21, 2022
Myocarditis is a rare complication resulting from the use of an immune checkpoint inhibitor (ICI) for treating a patient’s cancer. Yet, when it does develop, the chance of a patient dying from it are quite high. Now, researchers at Michigan Medicine report the development of new biomarkers that help for…
Published on December 2, 2022
Buoyed by a recent proof-of-concept trial of its cytoxic T lymphocytes (CTL) targeting treatment of SARS-CoV-2 infection, late stage biopharma Tevogen Bio announced will begin work to study potential therapeutic use of its allogeneic genetically unmodified precision T cell technology in multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific…
Published on November 16, 2022
Underprivileged children who receive CAR T-cell therapy for acute lymphoblastic leukemia (ALL) have similar outcomes as those from more advantaged households, according to a new study published in Blood. This is particularly surprising since, overall, children with ALL living in poverty are significantly more likely to relapse and die from…
Published on November 9, 2022
A new multi-center study has found that therapies which engage T cells such as bispecific antibodies and CAR-T cell therapies exhibit the most durable response in patients with relapsed or refractory multiple myeloma following BCMA-directed CAR-T cell therapy. The study, published in the journal Blood, was led by Sham Mailankody, MBBS, medical…
Published on October 27, 2022
Candel Therapeutics, a clinical stage developer of viral immunotherapies, announced Wednesday that it will collaborate with researchers at the University of Pennsylvania’s (UPenn) Center for Cellular Immunotherapies to study the efficacy of using viral immunotherapies to help boost the effects of UPenn’s CAR-T cell therapies in solid tumor models. The…
Published on October 7, 2022
Precision medicine company Tempus announced on Thursday that it will collaborate with Kartos Therapeutics to develop a companion diagnostic (CDx) to be used in the biopharma company’s ongoing Phase II clinical trial of navtemadlin (KRT-232), to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be eligible…
Published on October 5, 2022
A team of researchers at the University of Texas MD Anderson Cancer Center say they have developed a novel approach to the engineering of natural killer (NK) cells that improves tumor specificity and anti-tumor activity. The newly developed cells overcome NK cell dysfunction and tumor relapse via the addition of…